Novo Nordisk, Mounjaro and the question of who actually makes your medicine

The misconception worth clearing up first

It's genuinely common to see "Novo Nordisk Mounjaro" searched online, and understandable why: Novo Nordisk has been prominent in the GLP-1 space for years, partly through Ozempic's high public profile. The assumption that one company makes all the injectable weight-loss medicines is easy to form. In practice, Mounjaro belongs entirely to Eli Lilly, and the two companies are direct competitors in this category. Novo Nordisk's weight-management product is Wegovy, a weekly injection of semaglutide. Eli Lilly's is Mounjaro, a weekly injection of tirzepatide. They work through overlapping but distinct pathways, which is why their trial results differ, and why a prescriber's assessment of your individual situation is what guides the choice, not brand recognition alone.

If you're researching tirzepatide specifically, the tirzepatide overview covers the mechanism and evidence in detail.

What separates tirzepatide from semaglutide in practice

Tirzepatide is the only licensed weight-loss medicine in the UK that targets two gut-hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. Semaglutide targets GLP-1 alone. Both slow gastric emptying and reduce appetite, but the dual-receptor action of tirzepatide appears to produce a meaningfully larger average weight reduction in head-to-head evidence. In the SURMOUNT-5 trial, published in the New England Journal of Medicine (2025), tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. That said, individual responses vary, contraindications differ, and tolerability plays a real part in which medicine someone can sustain. A prescriber weighs all of that, not just the headline trial figure.

A fuller look at how Mounjaro is structured as a treatment (doses, schedule, what the KwikPen looks like) is on the Mounjaro treatment page.

Who the UK licence covers, and where NHS access fits

Mounjaro (tirzepatide) is licensed in the UK for adults with a BMI of 30 or above, or from 27 upwards where at least one weight-related health condition is present, conditions such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. NICE recommended tirzepatide for NHS use in December 2024 (updated September 2025), though NHS access is being phased in gradually based on BMI and number of qualifying comorbidities. Many people who are clinically eligible don't yet meet the current NHS cohort criteria, or simply don't want to wait. The route to Mounjaro without a GP referral explains how private prescribing works lawfully in that situation.

The NICE appraisal of tirzepatide (TA1026) sets out the full NHS eligibility criteria and the phased rollout timetable, worth reading if you're trying to understand where you might sit in the NHS queue.

Cost, supply and what to look for in a provider

Pricing for Mounjaro in the UK private market shifted materially from September 2025, when Eli Lilly raised the list price significantly. Reported private prices since then have ranged roughly from around £149 to £375 per month depending on dose and provider, and if you're based in the East Midlands, the Mounjaro Northampton page has locally relevant detail on accessing treatment. A transparent summary of the cost context is on the Mounjaro cost page. One thing worth noting: because both Mounjaro and Wegovy are prescription-only medicines, any UK pharmacy dispensing them must be registered with the GPhC. You can confirm a pharmacy's registration at the GPhC's online register. A legitimate provider will dispense only against a prescription issued after a genuine clinical assessment, and if you've come across compounded or unlicensed versions, the Nordic Labs tirzepatide page explains what to know about that particular product. Sellers offering these medicines without that process are operating outside UK law, and the MHRA has documented cases of counterfeit pens causing serious harm.

If you're weighing up your options and want to understand the treatment landscape more broadly, the weight-loss treatment overview covers both medicines alongside other licensed options.